Alkermes PLC (NAS:ALKS)
$ 24.46 0.33 (1.37%) Market Cap: 4.14 Bil Enterprise Value: 3.71 Bil PE Ratio: 9.67 PB Ratio: 3.30 GF Score: 70/100

Alkermes Plc at JPMorgan Healthcare Conference Transcript

Jan 15, 2020 / 05:00PM GMT
Release Date Price: $18.59 (+2.83%)
Cory William Kasimov
JP Morgan Chase & Co, Research Division - Senior Biotechnology Analyst

All right, all right. Good morning, everyone. My name is Cory Kasimov, senior biotech analyst at JPMorgan, and it's my pleasure to introduce our next company, which is Alkermes. Here to present for Alkermes is Chairman and CEO, Richard Pops and following Richard's presentation, there's a breakout down the hall to the [left] Olympic room. So with that, turn it over to Rich.

Richard F. Pops
Alkermes plc - Chairman & CEO

Thank you, Cory, and good morning, everybody. This is a period of intense activity at Alkermes. We've built a $1 billion top line business through developing a series of really important medicines that we're really proud of. But we're now focused on actively shaping the future of this business through an intense assessment of our products, our pipeline and even our corporate structure.

So if you haven't been watching closely, you probably haven't seen a number of the exciting changes that have been occurring, and that's what we're going

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot